MET and non-small cell lung carcinoma: These therapies include erlotinib, afatinib, gefitinib, osimertinib and dacomitinib for EGFR mutation positive NSCLC; crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib for ALK rearrangement positive NSCLC; crizotinib, entrectinib, and lorlatinib for ROS1 rearrangement positive NSCLC, dabrafenib and trametinib for BRAF V600E mutation positive NSCLC; larotrectinib and entrectinib for NTRK gene fusion positive NSCLC; capmatinib, crizotinib and tepotinib for MET exon 14 skipping NSCLC; and selpercatinib and pralsetinib for RET rearrangement positive NSCLC.